The 6 most recent market catalysts affecting $ARCT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 85
Why Is Arcturus Therapeutics Stock Gaining Thursday?
Arcturus Therapeutics released a series of positive updates, including favorable interim Phase 2 results for ARCT-810, indicating safety and efficacy in managing OTC deficiency. Co…
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 65
Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20
Citigroup analyst Yigal Nochomovitz upgraded Arcturus Therapeutics (ARCT) from Neutral to Buy and raised the price target from $8 to $20. This is a significant positive catalyst fo…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 75
Arcturus Therapeutics Says ARCT-810 Generally Safe And Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers In Ongoing Phase 2 Study
Arcturus Therapeutics reported encouraging interim Phase 2 results for ARCT-810, a drug targeting ornithine transcarbamylase (OTC) deficiency. The filing highlights the drug's safe…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 85
Arcturus Therapeutics Announces Interim Phase 2 Results From ARCT-810 In OTC Deficienc And Introduces LUNAR 2.0
Arcturus Therapeutics released several significant updates. The interim Phase 2 results for ARCT-810 in OTC deficiency were positive, showing safety, tolerability, and encouraging …
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 55
Arcturus Therapeutics To Present Overview Of ARCT-810 Phase 2 Clinical Program For Ornithine Transcarbamylase Deficiency And Arcturus’ mRNA Liver Therapeutics Platform On Sept. 23
Arcturus Therapeutics is holding a virtual presentation on September 23, 2026, to provide an overview of its ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 80
Arcturus Therapeutics Q2 EPS $(0.84) Beats $(1.00) Estimate, Sales $2.959M Miss $3.199M Estimate
Arcturus Therapeutics announced its Q2 earnings, revealing a mixed financial picture. While the company managed to beat analyst estimates for EPS, reporting a loss of $(0.84) again…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.